Natco Pharma Limited has informed the Exchange about press release dated 25-Jul-2022 titled Approval of its ANDA for Cabazitaxel Intravenous Solution (generic for Jevtana Kit��)
Press Release Jul 25 2022
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from NATCO Pharma
- NATCO Announces Launch of First Generic Version of Nexavar (Sorafenib) Tablets in the U.S. Market
- Press Release Jun 01 2022
- NATCO records INR 2043.8 Crore consolidated revenue and INR 170.0 Crore of profit, after tax, for the year ended March 31' 2022
- NATCO Announces Launch of the First Generic Version of Revlimid (Lenalidomide capsules), in the U.S. market
- Press Release Mar 07 2022
Later from NATCO Pharma
- NATCO records INR 918.9 Crore consolidated revenue and INR 320.4 Crore of profit, after tax, for the First Quarter, FY2022-23
- Press Release Aug 17 2022
- Press Release Sep 19 2022
- Press Release Sep 24 2022
- Press Release Oct 04 2022
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma